BACKGROUND: Advanced Therapy Medicinal Products (ATMPs) represent an innovative therapeutic approach with the potential to impact the treatment of rare diseases significantly. Although authorised centrally in the European Union, their market launch differs across Member States (MS). This study aimed to describe the ATMP market availability in MS and explore potential influencing factors, providing insights into specific barriers beyond pricing and reimbursement policies. METHODS: ATMP availability was defined as the product launch in each MS. Data was collected through open governmental sources, databases, and communication with national competent authorities. Spearman's correlation coefficients were calculated to examine the relationship between ATMP availability and their characteristics (time since granting marketing authorisation, target patient population size, and cost). RESULTS: We collected the availability data on 18 ATMPs from 23 EU MS. Market uptake varied significantly, with Germany (89%), France and Italy (61%) leading. Estonia and Latvia confirmed that no ATMP has been launched on their markets yet. Six ATMPs were available in more than one-third of the analysed MS. No significant correlation was observed between ATMP availability and analysed product characteristics except for time dependency for CAR T-cell therapies. CONCLUSION: Beyond pricing and reimbursement processes, the ATMP commercialisation in particular MS is influenced by the marketing authorisation holder's decision and capacity. ATMPs face product-specific challenges in achieving EU-wide availability, including complex manufacturing, distribution, and administration processes. To increase the accessibility of innovative ATMP-based treatments, implementing the cross-border access framework or individual ATMP production under the hospital exemption is essential, especially in underserved MS.

Centre of Excellence CREATIC Faculty of Medicine Masaryk University Kamenice 5 Brno 62500 Czech Republic

Department of Pharmacology Faculty of Medicine Masaryk University Brno Czech Republic

See more in PubMed

Public Health - European Commission. Union Register of medicinal products: Community Register of orphan medicinal products. https://ec.europa.eu/health/documents/community-register/html/reg_od_act.htm?sort=n. Accessed 26 April 2024.

European Medicines Agency. Committee for Advanced Therapies (CAT). https://www.ema.europa.eu/en/committees/committee-advanced-therapies-cat. Accessed April 23, 2024.

Alliance for Regenerative Medicine. Cell and Gene Therapy Sector Data. https://alliancerm.org/data/. Accessed 19 June 2024.

European Medicines Agency. Medicines for human use under evaluation. https://www.ema.europa.eu/en/medicines/medicines-human-use-under-evaluation. Accessed 15 July 2024.

Active Citizenship Network. European Charter of Patients’ Rights. Published online 2002. https://ec.europa.eu/health/ph_overview/co_operation/mobility/docs/health_services_co108_en.pdf. Accessed 26 June 2024.

European Medicines Agency. Seizing opportunities in a changing medicines landscape: The European medicines agencies network strategy 2028 (draft). https://www.ema.europa.eu/en/documents/other/seizing-opportunities-changing-medicines-landscape-european-medicines-agencies-network-strategy-2028-draft_en.pdf. Accessed 10 October 2024.

Gozzo L, Romano GL, Brancati S et al. Access to innovative neurological drugs in Europe: alignment of health technology assessments among three European countries. Front Pharmacol. 2022;12. PubMed PMC

Benazet F, Berard I, Prada M, et al. PPM11 market access landscape for advanced therapy medicinal products in the EU-5. Value Health. 2020;23:S688–9.

Walzer S, Prada M, Berard I et al. PBI38 innovative ATMPs: market access and reimbursement decisions in the EU5: availability or not, that is the question… value health. 2019;22:S424.

Gozzo L, Romano GL, Romano F, et al. Health technology assessment of advanced therapy medicinal products: comparison among 3 European countries. Front Pharmacol. 2021;12:755052. PubMed PMC

Ronco V, Dilecce M, Lanati E, et al. Price and reimbursement of advanced therapeutic medicinal products in Europe: are assessment and appraisal diverging from expert recommendations? J Pharm Policy Pract. 2021;14:30. PubMed PMC

Iglesias-López C, Agustí A, Vallano A, et al. Financing and reimbursement of approved advanced therapies in several European countries. Value Health. 2023;26:841–53. PubMed

Rejon-Parrilla JC, Espin J, Garner S et al. Pricing and reimbursement mechanisms for advanced therapy medicinal products in 20 countries. Front Pharmacol. 2023;14. PubMed PMC

Lif. Ny Rapp. Kortlægger Adgangen Til ATMP’er 11 Eur. Lande. Available from: https://www.lif.dk/23549-2/. Accessed 26 April 2024.

Kostadinov K, Marinova Y, Dimitrov K, et al. Navigating gene therapy access: the case of Bulgaria in the context of the EU regulatory landscape. Healthcare. 2024;12:458. PubMed PMC

Zamora B, Maignen F, O’Neill P, et al. Comparing access to orphan medicinal products in Europe. Orphanet J Rare Dis. 2019;14:95. PubMed PMC

Regulation (EC). No 1394/2007 of the European Parliament and of the Council of 13 November 2007 on advanced therapy medicinal products and amending Directive 2001/83/EC and Regulation (EC) No 726/2004 (Text with EEA relevance). OJ 324 10122007 P 121–137, Regulation (EC) No 1394/2007. http://data.europa.eu/eli/reg/2007/1394/oj

Directive 2001/83/EC of the European Parliament and of the Council of 6. November 2001 on the community code relating to medicinal products for human use. OJ 311 28112001 P 67–128, Directive 2001/83/EC. http://data.europa.eu/eli/dir/2001/83/oj

Gemeinsamer Bundesausschuss. Nutzenbewertung Nach § 35a SGB V. https://www.g-ba.de/bewertungsverfahren/nutzenbewertung/. Accessed 17 June 2024.

Státní ústav pro kontrolu léčiv. Seznam Referenčních Zdrojů SÚKL. https://sukl.gov.cz/zdroje-pro-cenovou-referenci/seznam-referencnich-zdroju-sukl/. Accessed 17 February 2024.

Ecker T, Le Mao J, Rossi L, et al. HPR111 ATMPs in Europe: do we have an access Gap? Value Health. 2023;26:S273.

AIFA Italian Medicines Agency. Innovative medicinal products. https://www.aifa.gov.it/en/farmaci-innovativi. Accessed 18 Jun 2024.

Detiček A, Locatelli I, Kos M. Patient access to medicines for rare diseases in European countries. Value Health. 2018;21:553–60. PubMed

Picavet E, Annemans L, Cleemput I, et al. Market uptake of orphan drugs – a European analysis. J Clin Pharm Ther. 2012;37:664–7. PubMed

Pejcic AV, Iskrov G, Jakovljevic MM, Stefanov R. Access to orphan drugs - comparison across Balkan countries. Health Policy Amst Neth. 2018;122:583–9. PubMed

Newton M, Stoddart K, Travaglio M et al. EFPIA Patients W.A.I.T. Indicator 2022 Survey. https://www.efpia.eu/media/s4qf1eqo/efpia_patient_wait_indicator_final_report.pdf. Accessed 25 April 2024.

Jørgensen J, Hanna E, Kefalas P. Outcomes-based reimbursement for gene therapies in practice: the experience of recently launched CAR-T cell therapies in major European countries. J Mark Access Health Policy.8:1715536. PubMed PMC

Newton M, Stoddart K, Travaglio M et al. June,. EFPIA Patients W.A.I.T. Indicator 2023 Survey. https://efpia.eu/media/vtapbere/efpia-patient-wait-indicator-2024.pdf. Accessed 18 2024.

Vogler S, Schneider P, Zimmermann N. Evolution of average European medicine prices: implications for the methodology of external price referencing. PharmacoEconomics Open. 2019;3:303–9. PubMed PMC

Ministerio de Sanidad. Profesionales de la Salud - Buscador situación financiación medicamentos. https://www.sanidad.gob.es/profesionales/medicamentos.do. Accessed 19 June 2024.

van Overbeeke E, Michelsen S, Toumi M, et al. Market access of gene therapies across Europe, USA, and Canada: challenges, trends, and solutions. Drug Discov Today. 2021;26:399–415. PubMed

Tunis S, Hanna E, Neumann PJ, et al. Variation in market access decisions for cell and gene therapies across the united States, Canada, and Europe. Health Policy. 2021;125:1550–6. PubMed

Jørgensen J, Kefalas P. Reimbursement of licensed cell and gene therapies across the major European healthcare markets. J Mark Access Health Policy. 2015;3. 10.3402/jmahp.v3.29321. PubMed PMC

Regulation (EU). 2021/2282 of the European Parliament and of the Council of 15 December 2021 on health technology assessment and amending Directive 2011/24/EU (Text with EEA relevance). OJ 458 22122021 P 1–32, Regulation (EU) 2021/2282. http://data.europa.eu/eli/reg/2021/2282/oj

Goula A, Gkioka V, Michalopoulos E, et al. Advanced therapy medicinal products challenges and perspectives in regenerative medicine. J Clin Med Res. 2020;12:780–6. PubMed PMC

Kamusheva M, Turcu-Stiolica A, Gierczyński J et al. Do advanced therapies have a future in the Low- and Middle-Income Countries - The case of Bulgaria, Romania, and Poland. Front Public Health. 2021;9. PubMed PMC

Alliance for Regenerative Medicine. Clinical trials in Europe: recent trends in ATMP development. October 2019. https://alliancerm.org/wp-content/uploads/2019/10/Trends-in-Clinical-Trials-2019-Final_Digital.pdf

Angelillo L, van Steen C, Ross-Stewart K, et al. Viability of European cross-border access opportunities to streamline access to ATMPs. Health Policy Technol. 2023;12:100752.

Olesen R, Larsen E, Birch CR et al. Kortlægning af anbefalede Avancerede Terapier (ATMP’er) i Danmark, Norge, Sverige og England. Nordic Institute of Health Economics (NIHE); 2024. Available from: https://assets-global.website-files.com/61f1a69593043f5cd512c750/662d24eb86f37f9c3c8545c7_Kortl%C3%A6gning%20af%20anbefalede%20Avancerede%20Terapier%20(ATMPer)%20i%20Danmark%20Norge%20Sverige%20og%20England_.pdf

Touchot N, Flume M. Early insights from commercialization of gene therapies in Europe. Genes. 2017;8:78. PubMed PMC

ICPerMed. Cross-border access to personalized treatment: the example of Strimvelis. https://www.icpermed.eu/en/strimvelis.php. Accessed 23 May 2024.

European Medicines Agency. Upstaza: EPAR - Product Information. https://www.ema.europa.eu/en/documents/product-information/upstaza-epar-product-information_en.pdf. Accessed 3 May, 2024.